Clinical trial
A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Active, not recruiting · Phase 1 · 2 countries · Registry ID NCT07225556
Active, not recruitingPhase 1Interventional
What this study is about
The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionOverweight, Obesity
Full registry criteria
Inclusion Criteria: * Participant must be 21 for Singapore site * Have a body mass index (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive * Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent \[%\] body weight change) Exclusion Criteria: * Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data. * Is an individual of childbearing potential (IOCBP)
Treatments and study arms
LY4167586
Drug
Administered SC
Placebo
Drug
Administered SC
LY4167586
Drug
Administered IV
Primary outcomes
Number and Incidence of Serious Adverse Events (SAEs)Baseline to study completion (up to 29 weeks)
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module